Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medbright AI Investments Inc MBAIF


Primary Symbol: C.MBAI

MedBright AI Investments Inc. is a capital allocator focused on investing in healthcare technology companies. The Company is engaged in constructing a portfolio of synergistic investments to generate returns for shareholders. The Company is focused on significant near-term and midterm opportunities with potential returns while maintaining a commitment to governance. It is focused on investing... see more

CSE:MBAI - Post Discussion

Medbright AI Investments Inc > LIFE & Special Warrant Offering for Gross Proceeds of $2.8M
View:
Post by MarketMakerss on Jan 25, 2024 5:41pm

LIFE & Special Warrant Offering for Gross Proceeds of $2.8M

Demonstrating the significant scalability of its tech alongside the size of its addressable market, MedBright AI (MBAI.c MBAIF) recently announced that Rejuvenation, a prominent dermatology group and leader in advanced dermatological care, is expanding its use of MedMatrix to include marketing for cosmetic treatments and clinical trial recruitment and data analysis.
 
Rejuvenation's extensive network includes 8 clinics spread across 3 provinces with a highly skilled team comprising of 21 dermatologists, 5 Mohs surgeons, 2 plastic surgeons, and 13 general practitioners specializing in dermatology.
 
With a mcap of only $22M, MBAI has been able to expand to 14 clinics, including a Yale University-Affiliated Clinic, and is strongly positioned to fix the $200 billion healthcare problem of congested waiting rooms. Successfully solving even a small percentage of the addressable market could mean quick multiples if they continue to execute on this path.
 
Plus, thisnews comes shortly after MBAI achieved its near-term goal of reaching US$100M in total clinic revenue under contract with MedMatrix.
 
MedMatrix
Focused on the intersection of healthcare and technology to match patient needs with enhanced revenue opportunities, MedBright AI (MBAI.c MBAIF) is the primary shareholder of and is targeting the healthcare waiting room problem with MedMatrix.
 
As detailed in this short introduction video, MedMatrix is an AI-powered data analytics platform and engine that analyzes crucial aspects of healthcare facilities and works alongside healthcare professionals to drastically improve healthcare operations and enhance clinic revenue by 10% at no additional cost to the clinic: https://youtu.be/f3bcx2T_GzQ?si=9CXluAYD43PEDMM9
 
In better aligning physician resources with patient needs, MedMatrix evaluates numerous factors related to a patient's background, clinical interaction history and other factors to predict the resource needs for their upcoming visits and optimize provider schedules, without the need for a new platform or additional training.
 
Latest News
Yesterday, MedBright AI (MBAI.c MBAIF) announced a LIFE & Special Warrant Offering for gross proceeds up to ~$2.8 million. The net proceeds will be allocated towards
 
 
Posted on Behalf of MedBright AI Investments Inc.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities